Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits powerful in vivo anti-glioblastoma activity
Malignant gliomas are the most common malignant and aggressive primary brain tumors in adults, the prognosis being—especially for glioblastomas—extremely poor. There are no effective treatments yet. However, tyrosine kinase receptor (TKR) inhibitors and boron neutron capture therapy (BNCT), together...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , , |
| Format: | article |
| Language: | English |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/20.500.12008/31990 |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits powerful in vivo anti-glioblastoma activity
- Structure-activity relationships of closo- and nido-carborane Erlotinib analogs: lipophilicity as a key modulator of anti-glioma activity
- Advancements in the synthesis and biological properties of carboranes and high‑boron related compounds: a comprehensive exploration with emphasis on BNCT applications
- Identification of N-oxide-containing aromatic heterocycles as pharmacophores for rumen fermentation modifiers
- Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
- Closo-carboranyl- and metallacarboranyl [1,2,3]triazolyl-decorated lapatinib-scaffold for cancer therapy combining tyrosine kinase inhibition and boron neutron capture therapy
- Tu Kit Gourmet